Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter...

Area of Science:

• Oncology
• Medical Oncology
• Clinical Trials

Background:

• Metastatic renal cell carcinoma (mRCC) presents a significant challenge, particularly after failure of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors.
• Identifying effective second-line treatment strategies is crucial for improving patient outcomes in mRCC.

Purpose of the Study:

• To assess the efficacy and safety of axitinib combined with toripalimab as a second-line treatment for mRCC.
• To evaluate outcomes in patients with mRCC who have progressed on prior VEGFR tyrosine kinase inhibitor therapy.

Main Methods:

• Retrospective data collection from 57 patients with mRCC.
• Kaplan-Meier analysis and Cox proportional hazards modeling were employed to determine efficacy endpoints.
• Safety was evaluated based on treatment-related toxicities.

Main Results:

• The combination therapy achieved an objective response rate of 31.6% with a median progression-free survival (PFS) of 11.7 months.
• Median PFS varied by risk group: not reached in favorable-risk, 11.0 months in intermediate-risk, and 7.8 months in poor-risk patients (p=0.011).
• Treatment-related toxicities were generally mild.

Conclusions:

• Axitinib plus toripalimab demonstrates potential as an effective second-line treatment for mRCC.
• This combination offers durable responses, extended PFS, and a manageable safety profile in this patient population.